Kancera AB Sustainability Reports
Kancera AB is a biotechnology company that develops small molecule drug candidates targeting the fractalkine axis to treat severe inflammatory diseases and cancer. Its clinical pipeline primarily focuses on treating hyperinflammation in myocardial infarction and treatment-resistant ovarian cancer.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 5493002P3RCOFW6HI207
No reports are currently available in our catalogue.